Literature DB >> 32355475

Pathophysiology of Alloimmunization.

Rubiraida Molina-Aguilar1,2,3, Soledad Gómez-Ruiz1, Jorge Vela-Ojeda1,2,3, Laura Arcelia Montiel-Cervantes1,2,3, Elba Reyes-Maldonado1.   

Abstract

INTRODUCTION: Alloimmunization is caused by exposure to erythrocytes from a donor that expresses blood group antigens other than those of the recipient and is related to processes that alter the balance of the immune system. Knowing the pathophysiology of alloimmunization process is essential to understand clinical complications associated with this process. PATIENTS AND METHODS: From October 2016 to April 2017, irregular antibody screening was performed in 1,434 polytransfused (compatible with the ABO and D system) patients by means of agglutination techniques using erythrocytes of a known phenotype of 44 patients with a positive alloantibody screening. Non-alloimmunized (control) subjects were matched for age, gender, pathology, and treatment group with alloimmunized patients. The subsets of B, T, and Treg lymphocytes were determined by flow cytometry.
RESULTS: The results of screening for alloantibodies in patients by specificity of antibodies were as follows: nonspecific (30%), followed by anti-Di<sup>a</sup> (13%), anti-e (9%), anti-S (9%), anti-I (7%), anti-K (7%), and anti-P (7%). A lower percentage of CD4+ T lymphocytes and an increase of CD8+ T lymphocytes were observed in alloimmunized patients, as well as a low CD4/CD8 ratio (0.7 vs. 1.6, p = 0.003), a higher percentage of B lymphocytes versus the control group (30 vs. 20%, p = 0.003), and a decrease of Treg CD4+ lymphocytes versus the control group (3 vs. 12 cells/μL, p = 0.043). These observations suggest that alloimmunized patients have important alterations in the number of some lymphocyte subsets that can be translated into clinical immune dysregulation.
CONCLUSION: A decreased CD4/CD8 ratio, increased B lymphocytes, and Treg lymphocyte deficiency are the most significant changes observed in alloimmunized patients.
Copyright © 2019 by S. Karger AG, Basel.

Entities:  

Keywords:  Alloantibodies; Alloimmunization; B lymphocytes; Regulatory lymphocytes; Transfusion

Year:  2019        PMID: 32355475      PMCID: PMC7184833          DOI: 10.1159/000501861

Source DB:  PubMed          Journal:  Transfus Med Hemother        ISSN: 1660-3796            Impact factor:   3.747


  28 in total

1.  Mechanisms of alloimmunization and subsequent bone marrow transplantation rejection induced by platelet transfusion in a murine model.

Authors:  S R Patel; N H Smith; L Kapp; J C Zimring
Journal:  Am J Transplant       Date:  2012-02-02       Impact factor: 8.086

2.  HLA type and risk of alloimmunization in sickle cell disease.

Authors:  Carolyn Hoppe; William Klitz; Elliott Vichinsky; Lori Styles
Journal:  Am J Hematol       Date:  2009-07       Impact factor: 10.047

3.  Expansion of regulatory CD8+ CD25+ T cells after neonatal alloimmunization.

Authors:  B Adams; A Dubois; S Delbauve; I Debock; F Lhommé; M Goldman; V Flamand
Journal:  Clin Exp Immunol       Date:  2010-12-22       Impact factor: 4.330

4.  Alloimmunization after blood transfusion in patients with hematologic and oncologic diseases.

Authors:  H Schonewille; H L Haak; A M van Zijl
Journal:  Transfusion       Date:  1999-07       Impact factor: 3.157

Review 5.  Responder individuality in red blood cell alloimmunization.

Authors:  Günther F Körmöczi; Wolfgang R Mayr
Journal:  Transfus Med Hemother       Date:  2014-10-28       Impact factor: 3.747

Review 6.  The Influence of Clinical and Biological Factors on Transfusion-Associated Non-ABO Antigen Alloimmunization: Responders, Hyper-Responders, and Non-Responders.

Authors:  Eric A Gehrie; Christopher A Tormey
Journal:  Transfus Med Hemother       Date:  2014-11-17       Impact factor: 3.747

7.  Positive association of DRB1 04 and DRB1 15 alleles with Fya immunization in a Southern European population.

Authors:  Chistophe Picard; Coralie Frassati; Agnes Basire; Stephan Buhler; Vital Galicher; Virginie Ferrera; Denis Reviron; Jean-Pierre Zappitelli; Pascal Bailly; Jacques Chiaroni
Journal:  Transfusion       Date:  2009-08-21       Impact factor: 3.157

8.  Inflammation enhances consumption and presentation of transfused RBC antigens by dendritic cells.

Authors:  Jeanne E Hendrickson; Traci E Chadwick; John D Roback; Christopher D Hillyer; James C Zimring
Journal:  Blood       Date:  2007-06-25       Impact factor: 22.113

Review 9.  Myelodysplastic syndromes current treatment algorithm 2018.

Authors:  David P Steensma
Journal:  Blood Cancer J       Date:  2018-05-24       Impact factor: 11.037

Review 10.  Blood Transfusion Therapy.

Authors:  Lawrence Tim Goodnough; Anil K Panigrahi
Journal:  Med Clin North Am       Date:  2016-12-24       Impact factor: 5.456

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.